key: cord-0768910-osl46w2q
authors: Piccioni, Andrea; Saviano, Angela; Cicchinelli, Sara; Franza, Laura; Rosa, Federico; Zanza, Christian; Santoro, Michele Cosimo; Candelli, Marcello; Covino, Marcello; Nannini, Giulia; Amedei, Amedeo; Franceschi, Francesco
title: Microbiota and Myopericarditis: The New Frontier in the Car-Diological Field to Prevent or Treat Inflammatory Cardiomyo-Pathies in COVID-19 Outbreak
date: 2021-09-16
journal: Biomedicines
DOI: 10.3390/biomedicines9091234
sha: 6c3f3dba6279605ee2eb2b92bb85c7a8e2bfdb72
doc_id: 768910
cord_uid: osl46w2q

Myopericarditis is an inflammatory heart condition involving the pericardium and myocardium. It can lead to heart failure, dilated cardiomyopathy, arrhythmia and sudden death. Its pathogenesis is mainly mediated by viral infections but also can be induced by bacterial infections, toxic substances and immune mediated disorders. All these conditions can produce severe inflammation and myocardial injury, often associated with a poor prognosis. The specific roles of these different pathogens (in particular viruses), the interaction with the host, the interplay with gut microbiota, and the immune system responses to them are still not completely clear and under investigation. Interestingly, some research has demonstrated the contribution of the gut microbiota, and its related metabolites (some of which can mimic the cardiac myosin), in cardiac inflammation and in the progression of this disease. They can stimulate a continuous and inadequate immune response, with a subsequent myocardial inflammatory damage. The aim of our review is to investigate the role of gut microbiota in myopericarditis, especially for the cardiovascular implications of COVID-19 viral infection, based on the idea that the modulation of gut microbiota can be a new frontier in the cardiological field to prevent or treat inflammatory cardiomyopathies.

Similarly, in animal models of experimental autoimmune myocarditis, an increase in microbial diversity and richness has been observed [9] . Interestingly, it was also observed that in different mice with different gut microbiota colonization profiles, susceptibility to autoimmune myocarditis varied immensely [10] .

The reduction of dysbiosis through antibiotics or other modern technique as fecal microbiota transplantation is able to modify the microbiome profiles in myocarditis mice, decreasing the inflammatory cardiac processes and the fibrotic cardiac dysfunction, the myocardial injury [10] .

To date, much more scientific evidence is emerging on the strong connection between the profile of the gut microbiota and cardiac health and diseases, but other clinical research studies are needed to understand this field and its application in clinical practice more clearly.

In addition, the spread of COVID-19 disease worldwide has prompted investigation into how to deal with viral infections that also have the potential of changing the composition of the gut microbiota [11] , influencing cardiac health [10] .

Studies about COVID-19 reported modifications in gut microbiota composition induced by the viral infection [12] [13] [14] [15] and in immune system functions [16] [17] [18] [19] [20] . In some cases, studies reported cardiac involvement with a cardiac disease (as inflammatory cardiomyopathies, myocarditis, and pericarditis) as a manifestation of COVID-19 infection [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] , too. To date, research to better clarify these topics is ongoing.

This narrative review included studies published in any language over the last 10 years, on the topic of microbiota and cardiovascular diseases, mainly focusing on cardiomyopathy and myopericarditis. In addition, we extended the search to include papers on COVID-19 and its impact on the development of myopericarditis, due to the presence of literature reports that underlined a connection between them. We searched systematic reviews, clinical trials, observational studies (longitudinal, cross-sectional, case-control, case series). We extracted data on the base on period of research, type of study, title, abstract. We searched on Web of Science ® , PubMed ® , UptoDate ® , Cochrane ® . No ethical approval was required to perform this review. The principal words we searched for were: microbiota AND cardiovascular diseases, microbiota AND COVID-19 AND/OR myocarditis, pericarditis AND microbiota, COVID-19 AND myopericarditis, Fecal transplantation AND/OR cardiovascular diseases, Dysbiosis AND viral infections AND cardiomyopathies.

In the process of viral invasion, the intestinal microbiota plays a key role, acting as a barrier, interacting directly or indirectly with the virus, and stimulating the innate and adaptive immune responses. Viral infections also have the potential of changing the composition of the gut microbiota [11] . Indeed, during COVID-19, modifications in microbiota composition have been reported [12] [13] [14] [15] . Patients with COVID-19 had a higher number of opportunistic pathogens and depletion of beneficial commensals. On the one hand, the baseline abundance of some pro-inflammatory bacteria such as coprobacilli and Clostridiodes was higher and correlated with a more severe disease course. On the other hand, antiinflammatory bacteria like Faecalibacterium prausnitzii, Eubacterium rectale and bifidobacteria were underrepresented. Interestingly, some bacteroides (B. dorei, B. thetaiotaomicron, B. massiliensis, and B. ovatus) downregulate the expression of angiotensin-converting enzyme 2 (ACE2), reducing the possibility of virus-entry thus causing a lower SARS-CoV-2 viral load in fecal samples of patients [13] [14] [15] .

Liu et al. studied the effect of fecal microbiota transplantation in 11 patients who recovered from COVID-19 and who had suffered with gastrointestinal symptoms, gut dysbiosis and alteration of their immune status. Fecal microbiota transplantation restored gut microbiota and alleviated gastrointestinal disorders, but also had an impact on the immune system as demonstrated by changes in the peripheral lymphocyte subset [16] . In addition, there was also an increase in Bifidobacterium and Faecalibacterium and restored Actinobacteria and Proteobacteria. The modulation of gut microbiota was also proven to reduce COVID-19 disease severity, with beneficial effects on gastrointestinal symptoms, too [16] . Additionally, other study groups are investigating the effects of gut microbiota modulation during COVID-19 infection. In particular, studies are focusing on the effects of microbiota in modulating the immune system of the host, particularly in terms of progression of cytokine storm. It is well known that gut microbiota strictly interacts with host immune system. Their relationship is complex and dynamic. Factors such as viral infections can modify this balance, triggering inflammatory and immune diseases [14] . However, many studies focusing on the interaction between immunity and microbiota have tried to sequence and characterize the microbiome's profile and to investigate on gut-microbiota modulators [13] [14] [15] [16] . Another aspect that has been investigated is the role of KB109, a synthetic peptide, that can act as a microbiota modulator. In two trials it is currently being investigated whether or not it could significantly and positively impact microbiota composition, as a positive effect of COVID-19 disease [17] [18] [19] .

The first reports in scientific literature regarding cardiac involvement during SARS-CoV-2 infection go back to the first months of the pandemic outbreak.

Many authors have described cases of patients with COVID-19 and inflammatory cardiomyopathies, mostly myocarditis [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] but also pericarditis [38] [39] [40] [41] [42] [43] . In some cases, the cardiac disease was the first manifestation of the viral infection [21, 29, 39] . In other patients it was a life-threatening early complication, [24, 25, 31, 38, 44] , or a fatal one [20] . Moreover, it could clinically display after infection recovery [30, 32, 35, 37, 45] , or sometimes remain subclinical, being detected only after cardiac imaging taking place for other reasons [46] . Manifestation could be cardiac tamponade or constrictive pericarditis, overall varying widely.

Acute myocardial dysfunction during the early course of COVID-19 has been retrospectively reported in 16-36% of patients [47, 48] . While the etiology is unclear, it has been suggested that cardiac damage in COVID-19 could be attributed to stress-induced cardiomyopathy and immunological and microvascular damage [49] .

The virus can indeed directly infect cardiac cells, entering in the endothelial blood vessels and activating immune response with endothelitis. Moreover, it can dysregulate hormonal pathways and activate proinflammatory responses with the release of many cytokines and the involvement of neutrophils, macrophages, platelets, and lymphocytes, thus provoking a prothrombotic state and a predisposition for clotting. This can happen both in the cardiac micro-and macro-vessels, with potentially many complications [49] .

Moreover, it can dysregulate hormonal pathways and activate proinflammatory responses, with the release of many cytokines and the involvement of neutrophils, macrophages, platelets, and lymphocytes, thus provoking a prothrombotic state and a predisposition for clotting. This can happen in the cardiac micro and macrovessels. There are many different possible consequences, which range from the above discussed myocarditis and pericarditis, but also sudden arrythmias, heart failure and cor pulmonaris, plaque rupture. Another manifestation, closely associated with stress-induced mechanisms, is Takotsubo syndrome [49] .

Post-mortem examination of hearts revealed potentially COVID-19-related cardiovascular histopathologic findings, such as macro or microvascular thrombi, inflammation, and presence of intraluminal megakaryocytes. Even if these manifestations have been reported in almost half of autopsies (47.8%), functionally significant myocarditis was identified in only 2% of all cases [50] . Interestingly, when analyzing myocardial biopsies of patients with myocarditis/myopericarditis, no evidence of intracellular virus was reported [51] . Yet, some authors reported the presence of SARS-CoV-2 mRNA in the endomyocardial biopsies of patients with clinically suspected myocarditis, both testing positive [52] or negative for COVID-19 by nasopharyngeal swab [53] . SARS-CoV-2 particles were found in the cardiac macrophages or in the endothelial cells [54] but not directly in cardiomyocytes; some authors have thus suggested that the cardiovascular damage was caused by overall immune activation, rather than by direct viral induced damage [55] .

The above discussed evidence has contributed to identifying and describing the "acute COVID-19 cardiovascular syndrome" (ACoVCS) in adults [56] . Yet, even though it has been identified as a clinical entity, its pathogenesis still remains largely unknown. Molecular mimicry and endothelial dysfunction have been hypothesized, but more studies are needed to confirm these results [51] .

Even if our review focuses on adult patients, it is interesting to note that the ACoVCS presents some similarities with the "multisystem inflammatory syndrome in children" (MIS-C) described by Most, that has been reported in children with SARS-CoV-2 infection [56] . At a cardiac level, the MIS-C can present itself with coronary dilatation, which resembles Kawasaki disease [55, 56] . Other manifestations can be elevated troponin, cardiogenic shock, and reduced biventricular function. In this study, all children tested negative for SARS-CoV-2 by polymerase chain reaction (PCR) test, but they also had specific IgG antibodies. The authors thus concluded that MIS-C could depend on a post-infectious inflammatory state that occurs several weeks after a primary infection [56] .

There is much more evidence on the association between COVID-19 and cardiovascular complications, such as myocarditis, pericarditis, fulminant myocarditis with arrhythmias, as described above, but there is a gap of knowledge in understanding the different pathogenic mechanisms [9] . Fox et al. analyzed myocardial biopsies of COVID-19 patients with myocarditis and found an increased number of CD68 + cells (that indicate monocyte/macrophage lineage), compared to myocarditis which are not associated to COVID-19 infection [57] . Similar observations have been reported by other authors as well [52] . The significance of these data has not been clarified yet and the possible association with prognosis and mortality is unclear. Lethal complications of myocarditis (such as end stage heart failure, cardiogenic shock, etc.) have also been observed in patients with COVID-19 infection [51] . Sawalha et al. noticed that cardiac tamponade was present in 20% of echocardiograms in patients with COVID-19 infection. Moreover, patients who died usually also had a serious acute respiratory distress syndrome as well [58] .

When considering clinical presentation, ACoVCS resembles other myocarditis. Indeed, patients mostly report oppressive chest pain or dyspnea, with an electrocardiogram that can be normal or may show alterations like ST-elevation or T-inversion. Troponin can be elevated above the normal value but does not typically present a significant delta between tests. Echocardiography can reveal a normal or reduced ejection fraction. Concerning the imaging of ACoVCS, as for other myocardiopathies, cardiac magnetic resonance seems to be the best diagnostic option [46, 59] . Esposito et al. found myocardial edema and wall thickening in eight patients with clinical suspect of myocarditis who underwent a cardiac MRI [59] . Authors concluded that inflammation was a substrate of myocardial injury in patients with SARS-CoV-2 infection. Further studies are necessary to fill the gaps and to solve the controversies as regards the direct and indirect effects of COVID-19 disease on myocardial cells and to better understand the cardiovascular consequences of its infection (Table 1) . 

Year Results

A 42-years-old died of ventricular fibrillation on day 9 after ICU admission for COVID-19 pneumonia. Her exams showed increasing troponin and NT-proBNP. The autopsy revealed myocarditis.

Beşler, M.S. et al. [21] 2020 Myocarditis has been the first manifestation of SARS-CoV-2 infection in a 20-years old female with no prior cardiovascular disease. 

Caballeros Lam, M. et al. [22] 2020

The paper reports two cases of people with SARS-CoV-2 infection and myocarditis. The first case is a young, asymptomatic, woman who tested positive in pre-partum screening. The delivery was regular, and she manifested chest pain a week later. Troponin was high and CMR revealed myocarditis. The second case is a 13-years-old boy without chest pain but with elevated troponin and NT-proBNP. The CMR detected myocarditis.

De Vita, S. et al. [23] 2020

A young woman presented to the ED with congestive heart failure-like symptoms one month after delivery. She reported flu-like syndrome few weeks before birth-giving. Her troponin, NT-proBNP, and d-dimer were high, and she tested positive for SARS-CoV-2 PCR. The chest CT-scan revealed pulmonary embolism, and CMR detected myocarditis with severe reduction of the ejection fraction (EF = 17%). Myocarditis can be a delayed manifestation of COVID-19, due to a multisystem inflammatory syndrome occurring several weeks after SARS-CoV-2 infection. This condition can be difficult to identify for many reasons: negative RT-PCR testing at the time of the cardiac presentation, attribution of systolic impairment to pre-existing cardiac disease, high frequency of COVID-19-related acute myocardial injury (up to 40% of hospitalised patients have increased troponin concentrations), and difficulties obtaining complex or invasive diagnostic investigations in ICU patients during the pandemic. A young woman with was evaluated in the ED for paucisymptomatic COVID-19 with normal exams and thoracic echography. She was discharged but represented 6 days after with pleuritic centrothoracic chest pain that improved when sitting forward and worsened with the supine position. The ECG, then laboratory findings and the echocardiography, were consistent with pericarditis. She was successfully treated as an outpatient with colchicine. Salamanca, J. et al. [44] 2020

A previously healthy 44-year-old man, previously discharged from the ED with paucisymptomatic COVID-19, returned few days later with shock signs. The ECG showed a third-degree atrioventricular block, the TTE revealed a non-dilated but globally and severely dysfunctional left ventricle and the troponin was high. With suspected fulminant myocarditis (further confirmed with CMR), the patient required mechanical ventilation, a temporary pacemaker, and vasoactive/inotropic support. Despite these measures his conditions worsened and he required ECMO and an intra-aortic balloon pump. He improved in the following days. 

A 31-year-old internal medicine registrar presented with dyspnoea on exertion and low-grade fever. He had a history of COVID-19 pneumonia and was discharged 3 weeks previously. The ECG, CRP, and troponin were normal. The TTE revealed mild left ventricular dysfunction. Suspicions of active myocarditis were confirmed with CMR.

Ng, M.Y. et al. [46] 2020

Case series of 16 patients who recovered from COVID-19 who underwent CMR to assess for evidence of myocardial involvement or ongoing myocarditis. CMR was performed at a median of 56 days post-recovery.

Lala, A. et al. [47] 2020

The intention of the authors was to describe the degree of myocardial injury and associated outcomes in a large hospitalized cohort with laboratory-confirmed COVID-19 (n = 2736). Cardiovascular disease including coronary artery disease, atrial fibrillation, and heart failure, was more prevalent in patients with higher troponin concentrations, as were hypertension and diabetes.

Wei, J.F. et al. [48] 2020

The authors prospectively assessed the medical records, laboratory results, chest CT images and use of medication in a cohort of patients (n = 101) presenting to two designated COVID-19 treatment centres in Sichuan, China. Acute myocardial injury was present in 15.8% of patients, nearly half of whom had a hs-TnT value five-fold greater than the normal upper limit

Topol, E.J. et al. [49] 2020

Cardiac injury, as reflected by elevated concentrations of troponin, is common with COVID-19, and occurs in at least one in five hospitalized patients and more than half of those with preexisting heart conditions. Such myocardial injury is a risk factor for in-hospital mortality, and troponin concentration correlates with risk of mortality.

Halushka, M.K. et al. [50] 2020

The authors performed a literature review on 277 autopsied hearts of COVID-19 positive patients. Even if potentially COVID-19-related cardiovascular histopathologic findings, such as macro or microvascular thrombi, inflammation, or intraluminal megakaryocytes, were reported in 47.8% of cases, myocarditis was present in 20 hearts (7.2%), and most cases were likely not functionally significant ( <2%). In conclusion, COVID-19-related cardiac histopathological findings are common, while myocarditis is rare.

Mele, D. et al. [51] 2021

The review aimed to summarize the limited knowledge about mechanisms, prevalence, prognosis, diagnosis and therapy of myocarditis in the context of COVID-19.

Bearse, M. et al. [52] 2021

The study focuses on 41 fatal cases of COVID-19. In such patients, infection of the heart by SARS-CoV-2 is common but is often limited with only rare infected cells. When present, myocarditis is often a relatively late event in the terminal disease course. Cardiac infection by SARS-CoV-2 is associated with electrocardiographic changes. Non-biologic immunosuppression is associated with lower incidences of both myocarditis and cardiac infection.

First report of two patients with a history of COVID-19 in whom clinically suspected myocarditis was supported by endomyocardial biopsy with evidence of persisting cardiac SARS-CoV-2 mRNA 

Myopericarditis is an inflammatory condition, in which a pericarditis and a myocarditis coexist [60] . The clinical presentation is often not specific; patients can experience chest pain and dyspnea and have an electrocardiogram with segment ST-elevation. For the diagnosis it is essential to rule out other etiologies, such as obstructive coronary disease. An echocardiogram can also be very useful in this context, as it can rule out some other causes of the symptoms experienced by the patient. The gold standard, in clinical practice, for the diagnosis is the cardiac magnetic resonance, which is useful for the identification of myocardial inflammation and damage [9] . A biopsy is required in selected cases, if the MRI is not able to provide a definitive diagnosis [61] . Myocarditis can also evolve into inflammatory cardiomyopathy, which is a medical emergency due to the high mortality risk. Genetic and environmental factors may predispose to progression and complications [62] .

In most cases, myopericarditis is caused by cardiotropic viruses [63, 64] , but bacterial infections, toxic substances and immune-mediated diseases have also been linked to the development of the condition [9] . In the case of viral infection, authors differentiate between a "cardiotopic effect" and a "lymphotropic effect". In the first case there is a direct, virus-induced, cardiac damage. In the second case, instead, there is an inflammatory cardiomyopathy, associated to the activation of the immune response, promoted by the virus, through a number of different immunologic pathways [9] .

With regard to the lymphotropic mechanisms, auto-inflammatory disorders are also a common manifestation and, overall, even if it is not the only and direct cause, autoimmune response is an important driver of heart disease progression.

In this context, studies on animal models focused on understanding the "crossmimicry" and the "cross reactivity" phenomena, and on the link between gut bacterial and cardiac inflammation [65] .

For example, Gil-Cruz et al. have observed that commensal gut bacteria like Bacteroides (vulgatus, diastonis, theta, thetaiotaomicron, faecis) or Enterococcus cloacae can produce myosin-like peptides. These peptides can cross-activate T-lymphocytes (Th1 and Th17 more specifically), promoting cardiotoxic damage [62] . These events lead to myopericarditis and dilative inflammatory cardiomyopathy [65] .

Besides "cross-mimicry", another mechanism has also been implicated in the development of the disease, consisting of the creation of a pro-inflammatory milieu promoted by dysbiosis. Indeed, while it is unlikely for these pathogens to directly damage the hearteven though bacterial translocation in the bloodstream has been described-it is likely that modifications in its composition can create an inflammatory environment, which can then precipitate the development of inflammatory cardiomyopathies [66] .

A study by Xiao-Fan et al. focuses on dysbiosis related to the onset of experimental autoimmune myocarditis (EAM) in murine models, in which it was shown that the progression of the disease is associated with an increase in the Firmicutes/Bacteroidetes ratio [4] . In another study, the correlation between myocarditis and the progression towards its complication, inflammatory cardiomyopathy, was analyzed [67] . It was observed that the progression also depends on the inflammatory stimulation by a species of Bacteroides in genetically pre-disposed individuals.

In the light of this evidence, the modulation of gut microbiota composition can be a potential treatment for acute cardiomyopathies. Mice with different microbiome patterns develop different forms of myocarditis, and antibiotics administration changes the progression of the disease [10] . Moreover, studies conducted on mice demonstrated that fecal transplant is effective in treating autoimmune myocarditis. Indeed, fecal microbiota transplantation led to reduction in myocardial injury and of inflammatory infiltration, with a decrease in IFN-γ gene expression in the heart tissue and CD4 + IFN-γ + cells in the spleen. Additionally, the ratio between Firmicutes and Bacteroidetes was restored [4] .

With regard to pericarditis, not many studies have been conducted on the relationship between the microbiota and their treatment. However, there is some evidence regarding the connection between Bacteroides and the onset of pericarditis. In particular, Bacteroides fragilis species can become pathogenic and give rise to a series of diseases including pericarditis [68] . For this reason, we believe that although there is currently not much evidence in this regard, in the future studying the relationship between microbiota and pericarditis will provide new therapeutic strategies to be used to improve patients' outcomes.

Cardiovascular diseases account for 31% of all global deaths and are the largest contributor to mortality and morbidity worldwide. With more and more developments in scientific research, the crucial and impacting role of gut microbiota in these pathologies has been proven and well demonstrated. Some data suggest that the gut microbiota could be able to improve prognosis of cardiovascular diseases, reducing several risk factors and its modulation is expected to become a new therapeutic approach [69] .

Viral infections are known to be able to alter the equilibrium in the gut microbiota. COVID-19 infection is also among the infections able to determine dysbiosis, which might also partly explain the correlation between myopericarditis and COVID-19 infection. Indeed, this disease caused an enrichment of opportunistic pathogens and depletion of beneficial bacteria. It is already documented that patients with cardiac failure show reduced capacity to absorb substrates and an increase in intestinal permeability, often characterized by reduced diversity of gut microbiota and imbalances between bacterial families [70] [71] [72] . Considering that at least in some viral infection processes, the intestinal microbiota seems to have a key role, it is more and more evident that viral infections may be able to change the microbiota composition. Moreover, observing that the gut microbiota seems to modulate the responses at least during some respiratory infections, this also could be the case for COVID-19 [73] . Ten gastrointestinal symptoms accompany influenza infection, and, in animal models, respiratory infection has been shown to alter the microbiota [73] [74] [75] [76] . Considering that the gut microbiota modulates the responses during respiratory infections, this also could be the case for COVID-19. Recent data demonstrated that COVID-19 patients have significant differences in gut microbiota composition and on the interaction between microbiota and host cells [73] . On the other side, as described in the introduction section, gastrointestinal dysbiosis can lead to cardiovascular diseases [2, 3, 77] and cardiovascular impairment can contribute to maintain gut microbiota dysbiosis [78] . In particular, many studies have described cases of patients with COVID-19 and inflammatory cardiomyopathies. Our review took into consideration the hypothesis that this triad, cardiomyopathies-COVID-19 infection-microbiota, is strongly connected. Recent evidence, both from animal and human studies, supports the idea that gut microbiota dysbiosis can play a role in cardiovascular diseases [79] . In particular, the dysbiosis can be responsible of cardiotoxicity and phenomenon of cardiac inflammation. Therefore, determining the COVID-19 infection a functional and taxonomic reshaping of gut microbiota, it is very likely the cardiovascular repercussions; large epidemiological studies and animal models are needed to better clarify this important correlation. Finally, modulating the gut microbiota could provide a favorable impact on the course of these conditions, but it is reasonable to say that more studies (animal models, but even more so clinical trials) are required to test the efficacy of therapeutic intervention on gut microbiota in cardiovascular diseases and employ them in clinical practice. 

COVID-19 and fecal microbiota transplantation: Limitations and potentialities are two sides of the same coin

Gut Microbiota in Cardiovascular Health and Disease

Gut microbiota derived metabolites in cardiovascular health and disease

Fecal microbiota transplantation alleviates myocardial damage in myocarditis by restoring the microbiota composition

Human oral, gut, and plaque microbiota in patients with atherosclerosis

Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: A prognostic marker for incident cardiovascular events beyond traditional risk factors

Intestinal microbiota determine severity of myocardial infarction in rats

Probiotic Administration Attenuates Myocardial Hypertrophy and Heart Failure After Myocardial Infarction in the Rat

Myocarditis and inflammatory cardiomyopathy: Current evidence and future directions

Regulation of autoimmune myocarditis by host responses to the microbiome

Intestinal Microbiota-A Promising Target for Antiviral Therapy? Front

Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19

Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19

Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19

Gastrointestinal disturbance and effect of fecal microbiota transplantation in discharged COVID-19 patients

Identifier NCT04486482, A Clinical Study to Assess the Physiologic Effects of KB109 in Patients with COVID-19 on Gut Microbiota Structure and Function

Identifier NCT04824222, the Impact of Fecal Microbiota Transplantation as an Immunomodulation on the Risk Reduction of COVID-19 Disease Progression with Escalating Cytokine Storm and Inflammatory Parameters

Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: A structured summary of a study protocol for a randomized controlled study

COVID-19-related fatal myocarditis in a 42-year-old female patient

Acute myocarditis associated with COVID-19 infection

Cardiac magnetic resonance characterization of COVID-19 myocarditis

Peripartum cardiomyopathy in a COVID-19-infected woman: Differential diagnosis with acute myocarditis-A case report from a Hub Institution during the COVID-19 outbreak

Myocarditis in a patient with COVID-19: A cause of raised troponin and ECG changes

Fulminant myocarditis due to COVID-19

A recovered case of COVID-19 myocarditis treated with IV immunoglobulin

COVID-19-related myocarditis in a 21-year-old female patient

Diffuse Myocardial Inflammation in COVID-19 Associated Myocarditis Detected by Multiparametric Cardiac Magnetic Resonance Imaging

Myocarditis revealing COVID-19 infection in a young patient

Delayed isolated peri-myocarditis in a Covid-19 patient with respiratory symptoms but without lung involvement

First case of COVID-19 complicated with fulminant myocarditis: A case report and insights

Delayed-onset myocarditis following COVID-19

COVID-19 myocarditis and postinfection Bell's palsy

SARS-CoV-2-Related Subacute Thyroiditis, Myocarditis, and Hepatitis After Full Resolution of COVID-19 Serum Markers

Diabetes Insipidus and Concomitant Myocarditis: A Late Sequelae of COVID-19 Infection

COVID-19-Associated Suspected Myocarditis as the Etiology for Recurrent and Protracted Fever in an Otherwise Healthy Adult

Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19

Acute pericarditis as a primary presentation of COVID-19

Pericarditis in a young internal medicine resident with COVID-19 in Colombia

Acute pericarditis due to COVID-19 infection: An underdiagnosed disease? Med

Pericarditis secondary to COVID-19 infection in a kidney transplant recipient

Coronavirus disease 2019 (COVID-19)-associated constrictive pericarditis

COVID-19 "Fulminant Myocarditis" Successfully Treated with Temporary Mechanical Circulatory Support

Myocarditis detected after COVID-19 recovery

Patients recovered from COVID-19 show ongoing subclinical myocarditis as revealed by cardiac magnetic resonance imaging

Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection

Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis

COVID-19 can affect the heart

Myocarditis is rare in COVID-19 autopsies: Cardiovascular findings across 277 postmortem examinations

Myocarditis in COVID-19 patients: Current problems

Factors associated with myocardial SARS-CoV-2 infection, myocarditis, and cardiac inflammation in patients with COVID-19

Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab

Cardiovascular complications of COVID-19

COVID-19: Consider cytokine storm syndromes and immunosuppression

Striking Similarities of Multisystem Inflammatory Syndrome in Children and a Myocarditis-Like Syndrome in Adults: Overlapping Manifestations of COVID-19

Pulmonary and cardiac pathology in African American patients with COVID-19: An autopsy series from New Orleans

Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome

Cardiac Magnetic Resonance Characterization of Myocarditis-Like Acute Cardiac Syndrome in COVID-19

StatPearls

Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy

Myopericarditis: Etiology, management, and prognosis

What's your gut telling you? How researchers are investigating the link between myocarditis and intestinal microbiota

A case of myopericarditis associated to Campylobacter jejuni in-fection in the southern hemisphere

Intestinal microbiota mimicry at the origin of lethal inflammatory cardiomyopathy

Comparative genomics of transport proteins in seven Bacteroides species

Gut Microbiota: A Novel Regulator of Cardiovascular Disease and Key Factor in the Therapeutic Effects of Flavonoids

Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: A systematic review and dose-response meta-analysis

Altered Intestinal Function in Patients With Chronic Heart Failure

Heart failure is associated with depletion of core intestinal microbiota

Intestinal Microbiota in the SARS-CoV-2 Infection: What Is Known? Single Mol

Influenza virus infection among pediatric patients reporting diarrhea and influenza-like illness

Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation

Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota

Gut Microbiota and Environment in Coronary Artery Disease

The gut microbiota and its interactions with cardiovascular disease

Calcific Aortic Valve Disease-Natural History and Future Therapeutic Strategies

Funding: This research received no external funding.Informed Consent Statement: Not applicable.

The authors declare no conflict of interest.